What is Remedy Plan?
Remedy Plan Therapeutics operates at the intersection of oncology and metabolic research, specializing in the development of small molecule therapeutics. The company is primarily recognized for its pioneering work in NAMPT inhibition, a biological pathway often implicated in various malignancies and metabolic disorders. Unlike traditional approaches that frequently encounter dose-limiting toxicities, Remedy Plan has engineered a mechanism that allows for hyperbolic, highly tunable inhibition.
This technological differentiation enables the company to target a diverse array of indications, including solid tumors, hematologic malignancies, obesity, and autoimmune conditions. By maintaining a robust pipeline of inhibitors, the firm is effectively positioning itself as a leader in next-generation drug discovery, focusing on efficacy without compromising patient safety profiles.
How much funding has Remedy Plan raised?
Remedy Plan has raised a total of $18M across 1 funding round:
Other Financing Round
$18M
Other Financing Round (2025): $18M with participation from Alexandria Venture Investments LLC Alexandria Venture Investments and Schooner Capital
Key Investors in Remedy Plan
Alexandria Venture Investments LLC
A venture capital firm that provides strategic financial support to early-stage companies, focusing on fostering innovation within the life sciences and technology sectors.
Schooner Capital
An established investment firm with a long history of supporting entrepreneurs and businesses through strategic guidance and capital allocation.
What's next for Remedy Plan?
Looking ahead, the strategic deployment of the $18M will likely focus on advancing the company's lead assets toward clinical validation. As Remedy Plan moves deeper into its development lifecycle, the focus will shift from foundational research to rigorous preclinical testing and regulatory preparation. The company's ability to maintain its tunable inhibition profile will be the primary metric for success as it seeks to establish partnerships or move toward human trials.
Furthermore, the firm is expected to expand its intellectual property portfolio, solidifying its market position in the NAMPT inhibition space. With the support of its current investor base, Remedy Plan is poised to navigate the complexities of the biotech sector, aiming to deliver transformative therapies that address significant unmet clinical needs in oncology and beyond.
